The combination preparation ipratropium bromide/salbutamol is a formulation containing ipratropium bromide and salbutamol sulfate (albuterol sulfate) used in the management of chronic obstructive pulmonary disease (COPD) and asthma (not an FDA approved usage). It is marketed by Boehringer Ingelheim as metered dose inhaler (MDI) and nebuliser preparations under the trade name Combivent. Besides, it is marketed by Dey, L.P. (Napa, California) under the brand name DuoNeb as a nebulizer.
Ipratropium bromide (INN, trade names Atrovent) is an anticholinergic drug used for the treatment of chronic obstructive pulmonary disease and acute asthma. It blocks the muscarinic acetylcholine receptors in the smooth muscles of the bronchi in the lungs, opening the bronchi.